LENZ Therapeutics (LENZ) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 12, 2026, to be held virtually for stockholders of record as of April 14, 2026.

• Proxy materials, including the notice, proxy statement, and annual report or Form 10-K, are available online, with paper copies available upon request.

Voting matters and shareholder proposals

• Election of three Class II directors to serve until the 2029 annual meeting or until successors are elected and qualified.

• Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

• Board recommends voting FOR all director nominees and FOR the auditor ratification proposal.

Board of directors and corporate governance

• Director nominees for election are Evert Schimmelpennink, Jeff George, and Shelley Thunen.